Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Johnson & Johnson

Stocks ended the week on a firm note, with the Dow Jones closing at a new high as bond yields eased and tech shares helped lift the broader market....

The Week That Was, The Week Ahead: Macro and Markets, May 24

Vanguard S&P 500 ETF ($VOO) remains one of the most popular choices for investors seeking broad exposure to the U.S. stock market. However, as mark...

Looking Beyond VOO? These 3 BlackRock ETFs Offer 20%+ Upside in 2026

Exchange-traded funds (ETFs) are popular for their ability to diversify risk by spreading investments across several securities/assets. However, th...

Best ETFs to Invest In, According to AI Analyst, 5/6/2026

Dividend ETFs are one of the easiest ways for investors to build long-term passive income without having to pick individual stocks. In 2026, three ...

3 Best Dividend ETFs for Investors Seeking Passive Income in 2026

Citi analyst Joanne Wuensch reiterated a Buy rating on Johnson & Johnson yesterday and set a price target of $285.00. According to TipRanks, Wuensc...

Market Cap	$459.32B	P/E Ratio	19.89
52W High	$251.71	52W Low	$149.04
Div Yield	536.0%	Payout Ratio	59.5%
EPS Growth 3Y	17.7%	52W Position	79.0%
Overall Score	49	Value Score	70
Quality Score	39	Technical Score	40

EPS Current Est	$11.57	EPS Next Est	$12.58
EPS Growth Est	+8.7%	DPS Growth 3Y	0.0%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	JNJ	$230.18	-1.21%	6.43M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	JNJ	$230.18	-1.2%	6.43M
3
4
5
6

JNJ

JNJ

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Johnson & Johnson Data in Excel

Get Johnson & Johnson Data in Excel